AstraZeneca PLC (LON:AZN) Receives GBX 6,303.50 Consensus Target Price from Brokerages

AstraZeneca PLC (LON:AZN) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is GBX 6,303.50 ($83.63).

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Berenberg Bank reissued a “buy” rating and issued a GBX 140 ($1.86) price target on shares of AstraZeneca in a research note on Wednesday, March 26th. Finally, Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Friday, March 7th.

AstraZeneca Trading Down 1.3 %

Shares of AZN stock opened at £101.24 ($134.32) on Tuesday. The stock has a market capitalization of £194.79 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 0.86 and a beta of 0.17. The company’s fifty day simple moving average is £113.41 and its two-hundred day simple moving average is £110.81. AstraZeneca has a 1 year low of GBX 9,573.51 ($127.02) and a 1 year high of £133.88 ($177.63). The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.